Intervention Review

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism

  1. Petra MG Erkens2,
  2. Martin H Prins1,*

Editorial Group: Cochrane Peripheral Vascular Diseases Group

Published Online: 8 SEP 2010

Assessed as up-to-date: 13 JUL 2010

DOI: 10.1002/14651858.CD001100.pub3

How to Cite

Erkens PMG, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD001100. DOI: 10.1002/14651858.CD001100.pub3.

Author Information

  1. 1

    University of Maastricht, Department of Epidemiology, Maastricht, Netherlands

  2. 2

    University of Maastricht, Department of General Practice, Maastricht, Netherlands

*Martin H Prins, Department of Epidemiology, University of Maastricht, PO Box 616, Maastricht, 6200 MD, Netherlands.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 8 SEP 2010


Cited in:


This article has been cited by:

  1. 1
    Jonas Kolbenschlag, Adrien Daigeler, Sarah Lauer, Gerhard Wittenberg, Sebastian Fischer, Nicolai Kapalschinski, Marcus Lehnhardt, Ole Goertz, Can rotational thromboelastometry predict thrombotic complications in reconstructive microsurgery?, Microsurgery, 2014, 34, 4
  2. 2
    Y. H. Khor, R. Smith, C. F. McDonald, Suboptimal management of unfractionated heparin compared with low-molecular-weight heparin in the management of pulmonary embolism, Internal Medicine Journal, 2014, 44, 4
  3. 3
    Luciano A. Sposato, Osvaldo Fustinoni, Neurologic Aspects of Systemic Disease Part III, 2014,


  4. 4
    Kate Burbury, Haemostatic challenges in the cancer patient: Focus on the perioperative period, Best Practice & Research Clinical Anaesthesiology, 2013, 27, 4, 493


  5. 5
    Javier Trujillo-Santos, Sebastian Schellong, Conxita Falga, Vanessa Zorrilla, Pedro Gallego, Manuel Barrón, Manuel Monreal, Low-molecular-weight or Unfractionated Heparin in Venous Thromboembolism: The Influence of Renal Function, The American Journal of Medicine, 2013, 126, 5, 425


  6. 6
    Jeffrey A Kline, Jackeline Hernandez, Melanie M Hogg, Alan E Jones, D Mark Courtney, Christopher Kabrhel, Kristen E Nordenholz, Deborah B Diercks, Matthew T Rondina, James R Klinger, Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes, Emergency Medicine Australasia, 2013, 25, 6
  7. 7
    Christopher Patriquin, Mark Crowther, Consultative Hemostasis and Thrombosis, 2013,


  8. 8
    Claire MCLINTOCK, Tim BRIGHTON, Sanjeev CHUNILAL, Gus DEKKER, Nolan MCDONNELL, Simon MCRAE, Peter MULLER, Huyen TRAN, Barry N.J. WALTERS, Laura YOUNG, Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period, Australian and New Zealand Journal of Obstetrics and Gynaecology, 2012, 52, 1
  9. 9
    Sherab Bhutia, Peng F Wong, Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism, The Cochrane Library,